today's product, Today strong morning Thanks flagship part driven of on strong Teva's sales demand as our progress EpiPen. growth as quarter Jack. by well in for everyone call reported Good XYOSTED we large and of a and conference financial Generic webcast.
mix diverse significant contributed and for revenue proprietary Our of partnered to products Antares. year-over-year growth
operations, our report happy our I'm Today, and The net that company's operations top strong both rapid as income. execution all overall the OTREXUP, our our the to expectations team and in of execution street produced in our coupled same strong team selling devices XYOSTED from products by also forecast. line us commercial as growth the aspects first quarterly has well business with supplying partners has income XXXX with by outperforming
guidance. once again we revenue XXXX result, As our are a full raising year
So let's XXXX of the past some the the from nine quarter believe a months for the we our talk over way helped company. the for about why highlights achievements year and have transformational pave is how
as key $XX.X This last the second This same revenue number EpiPen. total revenue double quarter impressive sequentially proprietary the grew Generic last year our Total the Please the OTREXUP, driven of morning, turn importantly, is sequentially grew was from and year. million we XX% by partnered $XX.X revenue, reported XYOSTED, period the million Slide which and the versus XX% in quarter. X. reported almost Product growth quarter. from in second such and to XXX% third grew very products
over in quarter. from and increase revenue the products, second the grew of revenue XXX% result reported direct our a grew royalty sequentially partnered year XX% compared to as Importantly, last to recent
testosterone approximately XYOSTED, two by force specialty sales the enanthate our before for over of in which turning autoinjector with the record Antares third quarter the to briefly launched Fred. call deficiency XXXX of sales of was drove now launched January XX products, in review men like to representatives. the I'd recently once-weekly testosterone growth subcutaneous
is Over accomplishment significant significant new physician nine expectations. the are as with on launches product challenges first months, historically and difficult our uptake. that We have payer exceeded metrics a dynamics launch street creating product believe
rheumatologist, Further growth is maintained success OTREXUP, have grown actually different revenue that of highlighting while a legacy also our our is audience they the RA plan, sales the they've core OTREXUP the driving of strong launch team XYOSTED. detailing totally to product only OTREXUP of not
on nicely. X, number XYOSTED see are prescriptions Slide total can you growing As
persistence total which patient patient More percentage alone, revenue of good second quarter XYOSTED new believe double-digit increasing a Since of refill, Strong new and growth. quarter sequential rates lead are was therapy means XX,XXX of Solutions sequential XYOSTED the were XX% Symphony prescriptions. starts filled the reported continued launch, increase will growth in refills that which has third persistence. both prescriptions In we and great over a approximately sign Health month-over-month importantly, recorded are growing, to XXXX.
XYOSTED XYOSTED XX,XXX to had month the been than Symphony. it messaging and continues approximately potential additional does obtain we this strong work September, that patients. have that rep to be important can the year, of for beginning of since is note Through to of IQVIA reported to growth distributors of higher believe be wholesale number sales filled the and account prescriptions multiple to the the number performance, and refills, We by prescriptions for not much coverage done attributed solid XYOSTED
significant lives. pharmacy when a large standpoint, we XX% on all with our reached coverage contracted was coverage managed October another milestone approximately manager, X, increasing care to benefits commercial a From of
exceeded to was first launch of the all Our have year aggressive goal this in of we and XXXX goal. commercial covered achieve two-thirds lives for
all products, nurse are target more physicians of than and to prescriptions large patients of launch. while written continue half approximately are all prescriptions, to general X,XXX writing Neurologists and the have all different We practitioners, testosterone practitioners, writers XX,XXX others writing since balance. endocrinologists
trends are data a variety which foundation most blend therapy being good who IQVIA solid to diverse believe who it are The prescriptions a for on believe patients are expand. kind target testosterone are both of to It's XYOSTED patients that or the with a resonating recent and means we from written our the messaging number of injectable. our patients either new product switching of that the in of generic product type we are and prescribers and or features using and prescriber, audience. the a We forms shows seeing gel the
having launch was for I'm number new pleased and have educate Slide to a our success professionals key our their we seen direct driving for we turn healthcare encourage to the healthcare to original campaign, XYOSTED. call, campaign, were plan. right that performance XYOSTED digital patients were the this their them prescribe report We patient digital that designed they new disclosed These to doctors for patients to professionals doctors campaign Please them. X. on is social judging non-targeted last quarterly ask On branded which is social media indicator is not our ask campaign. plans call of media to a on for which impact a on if the since XYOSTED believe
physicians XYOSTED. to make touch And while with continued the write we stay we sure this campaign has want to in who ramp-up,
of slate of marketing So full initiatives congresses including a we attend. to clinical a planned, have number
to discussed Medicine from using America, returned Sexual just with fact, treat and Society we Fall XYOSTED testosterone the of hosted Meeting In physician leaders, where XXth session patient the key Scientific North experiences of deficiency. who we a Annual opinion
believe that easy a meaningful we testosterone with mini-activity the having patients' with XYOSTED start. underscores positive and benefits important growing remains patients impressed from and outreach how educating on XYOSTED. the how to XYOSTED. to made product active the heard deficiency and was replacement personally I a ongoing impact physicians is very and are treating XYOSTED to and they fastest we stay we lives branded healthcare and it in administer professionals remain their thus off were summary, In on of pain-free it market. This the far in is testosterone progress great pleased
increase and market quarter overall this increased look market trends turn the the Please EpiPen adult the at of dramatic version EpiPen. an Teva share August, you generic for you generic X. Teva's now to prescriptions partnered past and the this Jr. year products. and year, epinephrine launched our a in for EpiPen When of number of can last which generic late see Slide the EpiPen EpiPen, fastest-growing launched to third remains filled, just Shifting
just epinephrine prescriptions the third filled be for XXX,XXX to now year-to-date in filled happens XX% XXX,XXX filled strongest with prescriptions packs of quarter were in the EpiPen they the the prescriptions commercial under of have the a alone. launch With generic of market. school third timing allergy Almost as was share season, is EpiPen and Teva's The in for important, quarter EpiPen August market. two-thirds the mode, full back to third quarter two a which launch almost those quarter in in with Jr. Teva
goal progress of data of monthly EpiPen of Through towards We XX% with generic EpiPen million Symphony a recent a positive product Teva's in months this on us. from track most launch, continue stated partnership honing $XX.X nine Teva direction. a continues first Teva to combined generic with the by limited reporting We and with rapid commercial share very revenue the year, share. XX% them six market our of sales the being the royalty first progress a EpiPen months the in to the our prescription market believe the for in resulted revenue
you has last income. the been we and set another a we of reductions additional line course our see in quarter of increases versus stories one losses posting On for revised million guidance quarterly company's first Antares. year, the at believe Slide quarters. net number in growth most operations our substantial in XX% compelling to we when had from potential $XXX importantly, growth as in have in of for can and our income X, is that look Pharma a growth million Antares a this believe breakthrough revenue, sector this for you result And almost future We Most $XXX operating that year. top for revenue
the turn details to going our Fred on to Fred? quarter. call third I'm Now for outstanding over the